Detalles de la búsqueda
1.
Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019.
BMC Infect Dis
; 22(1): 36, 2022 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34991499
2.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794206
3.
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Oncologist
; 26(7): e1133-e1142, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909934
4.
Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia.
BMC Infect Dis
; 21(1): 572, 2021 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34126951
5.
Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry.
Hemoglobin
; 45(2): 80-86, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980108
6.
Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US.
Front Oncol
; 12: 786124, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35280795
7.
Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters".
Pharmacotherapy
; 40(9): 889-901, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33112456
8.
No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).
Maturitas
; 142: 38-44, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33158486
Resultados
1 -
8
de 8
1
Próxima >
>>